Kesimpta (ofatumumab) dosing is monthly after the initial loading phase, so when people ask about “average monthly cost,” they usually mean the out-of-pocket cost after insurance—but that varies a lot by plan (commercial vs Medicare/Medicaid, deductible status, formulary tier, copay/coinsurance, prior auth requirements, and whether a manufacturer copay program is allowed).
What patients typically see (general ranges)
- With commercial insurance (typical case): often ~$0–$300/month out-of-pocket, if the patient qualifies for/supports a copay program and the drug is on formulary.
- If not eligible for copay assistance / high deductible plans / Medicare coverage with higher patient cost-sharing: out-of-pocket can be hundreds to >$1,000/month.
- Without insurance: the cash price is much higher (often several thousand dollars per month), but you asked specifically with insurance.
Why I can’t give a single “average monthly cost” number
There isn’t a single reliable nationwide “average” that applies to all patients because the manufacturer’s assistance programs and payer structures lead to large variation.
If you want a more patient-usable estimate
If you tell me any of the following, I can narrow it down to a more realistic range for your patients:
- Insurance type: commercial vs Medicare vs Medicaid
- Location (state) (optional but helpful for Medicaid rules)
- Approximate plan design: deductible met vs not met; copay vs coinsurance
- Whether an assistance program is likely allowed (some patients on Medicaid may differ)
- Whether you mean cost to patient or total cost to insurer
If you share “commercial plan, deductible typically met / not met” (or similar), I’ll provide a tighter estimate range and the practical steps to obtain an accurate quote (specialty pharmacy benefits check, prior auth, copay card/bridge programs, etc.).